United StatesÚltimas notícias

Natera (NASDAQ:TRA) has entered into a clinical collaboration with Diakonos Oncology to deploy its liquid biopsy technology to track patient responses during an active trial for an aggressive skin cancer therapy.

BeOne Medicines (NASDAQ:ONC) is moving to advance the treatment paradigm for chronic lymphocytic leukemia (CLL) with extensive long-term follow-up data slated for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Australian Deputy Prime Minister Richard Marles says his country spends a larger share of its GDP on the military than major European nations. He speaks with Haslinda Amin from the sidelines of the Shangri-La Dialogue.

Shares of Dell Technologies (NYSE:DELL) soared nearly 40% in premarket trading on Friday after robust demand for its Nvidia-powered artificial intelligence servers prompted the hardware giant to sharply raise its annual revenue and profit forecasts.

BitFuFu (NASDAQ:FUFU) reported a decline in first-quarter revenue as a volatile downturn in Bitcoin valuations triggered a heavy asset write-down, eclipsing operational growth across the company's core cloud infrastructure services.

Oil prices stabilized on Friday but remained on track for their sharpest weekly decline since early April, as investors weighed reports of a tentative ceasefire extension between the U.S. and Iran against a backdrop of lingering political hurdles.

Seema Shah, Chief Global Strategist at Principal Asset Management, discusses the outlook for bond yields, equities pricing and Federal Reserve Policy. "It's gonna be important to watch how the bond yield market progresses," Shah says on Bloomberg Television. "From our perspective, though, we don't expect to see markets repricing Fed cuts."

SpaceX is currently targeting a valuation of at least $1.8 trillion in its initial public offering, according to people familiar with the matter. Bloomberg News reported in April that SpaceX was aiming for a valuation above $2 trillion. The target is settling lower after consultations with advisers and investors, the people said, asking not to be identified as the information isn't public. Matthew Bloxham of Bloomberg Intelligence has more.

The U.S. Food and Drug Administration approved AstraZeneca's (NYSE:AZN) blockbusting immunotherapy Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, marking a major regulatory expansion for the company’s oncology franchise into earlier-stage disease.

Blue Origin's New Glenn rocket exploded in a massive fireball while undergoing a test on a Florida launchpad Thursday evening, dealing a major setback to the Jeff Bezos-backed firm in its efforts to challenge a dominant SpaceX. Blue Origin and Amazon founder Jeff Bezos said it was too early to determine the cause of the explosion and described it as "a very rough day" in a post on X. Bloomberg Intelligence analyst Matt Bloxham joined Caroline Hepker to discuss the implications.

Joumanna Bercetche, Tom Mackenzie and Paul Dobson break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade."

Control Risks Partner Angela Mancini believes the outlook for a sustainable peace that meets the priorities of the primary threat actors in the Iran war remains very poor. She speaks with Haslinda Amin on "Insight with Haslinda Amin."